Lifeboat Foundation

Right in moment when Olympic games 2018 had started, founders of DAYS longevity accelerator and one of renowned longevity organizations leader have decided on running a sort of Olimpic games in life science, aiming to identify the world champions in area that really matters for everyone (life extension).

W hat is problem, why so important issue have no visible signs of progress?

If you’re sort of between 40 and older male, 40% of you will never reach the age of 74. Why multiple brilliant inventions of diagnostic and cure technologies have no financing and adoption in clinics?

https://www.stitcher.com/podcast/reaching-the-finish-line/e/…oplay=true

Nebula Genomics aims to help people understand their genome and guarantees that individuals will retain permanent ownership of their DNA data, all paid for with a new cryptocurrency.

What progress is being made in the field of reversing aging — the grand humanitarian project to extend healthy lifespan?

In this London Futurists online video conference, a number of healthspan extension researchers and activists from around the answered questions such as:
• What do you know now, that wasn’t known, or which was less clear, back in January 2017?
• What progress has encouraged you? And what disappointments have there been?
• Overall, what have we learned? And what should the field do differently in the future?

Continue reading “Reversing Aging — 2018 update” »

SGLT2 inhibitors, a promising class of diabetes drugs, were shown to significantly lower the rates of heart failure and death in the large CVD-REAL study.

Summary: A team of scientists at Tongji University just announced a breakthrough in regenerating human lungs using stem cells, improving lung function in patients. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

A team of researchers from Tongji University in China announced what they say is a breakthrough in treating lung diseases by regenerating tissue using stem cell transplantation.

In a pilot clinical trial, the treatment proved effective at repairing the lung tissue of two patients suffering from lung diseases, who showed improvements in both symptoms and on CT scans, say the researchers. Zuo Wei is a Tongji University professor who led the research team and says.

Continue reading “Researchers report breakthrough in human lung regeneration” »

Summary: A research team at UCSD discovered a key enzyme that plays a role in burning calories during both obesity and dieting and sabotages weight loss. Moreover, these scientists may have just found an existing drug that counteracts this enzyme. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

Ever wonder why dieting often leads to a plateau in weight loss? It happens because the body is trying to maintain a steady weight by regulating the expenditure of energy. How this happens has remained a mystery until now.

In a paper published on February 8 in the journal Cell, a team of researchers at the University of California San Diego (UCSD) School of Medicine led by Alan Saltiel, Ph.D. has identified a key enzyme that sabotages weight loss efforts during dieting. Dr. Saltiel is the director of UCSD’s Institute for Diabetes and Metabolic Health, and says.

Continue reading “Researchers discover key enzyme sabotaging our weight loss” »

The AHA names evolocumab — a new PCSK9 inhibitor — as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8, 2018. However, this novel cholesterol-lowering drug carries a big price tag.

Summary: The AHA names the PCSK9 inhibitor evolocumab as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8. However, this novel cholesterol-lowering drug carries a big price tag. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

The AHA named the cholesterol-lowering drug evolocumab in its annual top 10 lists of major advances in heart disease and stroke research, published on February 8. Evolocumab belongs to a class of cholesterol-lowering drugs called PCSK9 inhibitors and is injectable drug marketed by Amgen under the brand name Repatha. The two-year FOURIER study reported that evolocumab reduced high cholesterol levels and had few adverse effects.

Continue reading “AHA names PCSK9 inhibitor evolocumab as a top advance in heart disease” »

In a first for medical science, scientists in the UK have successfully created functioning human kidney tissue that produces urine.

Summary: In a first for medical science, researchers in the UK have successfully created functioning human kidney tissue that produces urine. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

In a first for medical science, researchers have successfully created human kidney tissue within a living organism which can produce urine.

Continue reading “Researchers create functioning kidney tissue” »